A detailed history of Amundi transactions in Replimune Group, Inc. stock. As of the latest transaction made, Amundi holds 2,513 shares of REPL stock, worth $37,519. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,513
Previous 2,513 -0.0%
Holding current value
$37,519
Previous $22,000 22.73%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$5.01 - $9.46 $1.23 Million - $2.32 Million
-245,567 Reduced 98.99%
2,513 $22,000
Q1 2024

May 15, 2024

BUY
$6.87 - $9.31 $505,851 - $685,513
73,632 Added 42.21%
248,080 $2.03 Million
Q4 2023

Feb 14, 2024

SELL
$6.75 - $16.18 $2.75 Million - $6.6 Million
-407,640 Reduced 70.03%
174,448 $1.47 Million
Q3 2023

Nov 14, 2023

BUY
$15.96 - $22.18 $2.08 Million - $2.88 Million
130,041 Added 28.77%
582,088 $9.96 Million
Q2 2023

Aug 14, 2023

BUY
$15.65 - $24.1 $783,000 - $1.21 Million
50,032 Added 12.45%
452,047 $10.5 Million
Q1 2023

May 15, 2023

SELL
$17.48 - $29.09 $339,583 - $565,131
-19,427 Reduced 4.61%
402,015 $7.1 Million
Q4 2022

Feb 14, 2023

BUY
$17.09 - $27.91 $961,842 - $1.57 Million
56,281 Added 15.41%
421,442 $11.5 Million
Q3 2022

Nov 14, 2022

SELL
$15.6 - $21.15 $139,651 - $189,334
-8,952 Reduced 2.39%
365,161 $6.44 Million
Q2 2022

Aug 15, 2022

BUY
$13.32 - $19.98 $762,689 - $1.14 Million
57,259 Added 18.07%
374,113 $7.57 Million
Q1 2022

May 16, 2022

SELL
$15.24 - $29.75 $321,122 - $626,862
-21,071 Reduced 6.24%
316,854 $6.27 Million
Q4 2021

Feb 14, 2022

SELL
$25.43 - $34.25 $421,934 - $568,276
-16,592 Reduced 4.68%
337,925 $7.88 Million
Q3 2021

Nov 15, 2021

BUY
$28.98 - $39.54 $2.34 Million - $3.2 Million
80,822 Added 29.53%
354,517 $10.5 Million
Q2 2021

Aug 16, 2021

BUY
$28.5 - $39.37 $7.8 Million - $10.8 Million
273,695 New
273,695 $10.5 Million

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $736M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Amundi Portfolio

Follow Amundi and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.